Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-08-07
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud software, and workflow tools that aim to broaden imaging access across clinicians, health systems, educators, and partners.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable Imaging Becomes a Workflow Business
The upside case is not just more handheld scanners. The real prize is turning each exam into software, licensing, and regulated workflow revenue while proving new channels monetize on schedule.

Analysis

Thesis
Butterfly can roughly double equity value by 2031 if it converts from a premium handheld ultrasound vendor into a regulated imaging workflow and embedded-chip platform; AI expands who can scan, but the real value unlock is capturing more of each exam through software, compliance, and partner licensing.
Last Economy Alignment
AI makes ultrasound easier to acquire, review, and deploy in more settings, and Butterfly owns a real hardware-plus-workflow control point. It benefits materially from cheaper cognition, but capture is capped unless software and licensing become durable profit pools.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
I underwrite solid core probe growth, better enterprise software attach, and a meaningful but not heroic embedded ramp. That mix should make the business look less like a one-time device seller and more like a workflow-plus-licensing platform, but current optimism is already high, so I still assume valuation normalizes from today’s rich level.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly has a real product; it does. The main risk is whether high-margin layers like embedded licensing, enterprise workflow, and regulated channel access scale fast enough to justify a platform valuation before larger incumbents and normal valuation gravity catch up.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.35
AI makes ultrasound easier for more clinicians to use, and Butterfly controls the probe, the cloud record, and parts of the workflow around each scan. The risk is that larger imaging vendors copy enough of the experience and use existing hospital relationships to keep Butterfly from owning the value layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$8.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case